Management believes that the Company’s cash and cash equivalents are sufficient to fund operations and capital requirements into mid-year 2024. Top-line results from the Company’s confirmatory pivotal Phase 3 RECONNECT trial of Zygel in patients with FXS are expected in the first half of 2024."We remain focused on enrolling patients in our confirmatory pivotal Phase 3 RECONNECT trial, and expect topline results in the first half of 2024," said Armando Anido, Chairman and Chief Executive Officer of Zynerba. "We are committed to bringing the first pharmaceutical product indicated for the treatment of behavioral symptoms of Fragile X syndrome to market, and with a cash runway to mid-year 2024, we remain well-positioned on achieving that goal."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ZYNE:
- Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
- Zynerba confirms does not hold cash deposits, securities at Silicon Valley Bank
- Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank
- Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
- Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference
